|
1
|
Massagué J: TGFbeta in cancer. Cell.
134:215–230. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cipriano R, Kan CE, Graham J, Danielpour
D, Stampfer M and Jackson MW: TGF-β signaling engages an
ATM-CHK2-p53-independent RAS-induced senescence and prevents
malignant transformation in human mammary epithelial cells. Proc
Natl Acad Sci USA. 108:pp. 8668–8673. 2011; View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schiller M, Javelaud D and Mauviel A:
TGF-beta-induced SMAD signaling and gene regulation: Consequences
for extracellular matrix remodeling and wound healing. J Dermatol
Sci. 35:83–92. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Flavell RA, Sanjabi S, Wrzesinski SH and
Licona-Limón P: The polarization of immune cells in the tumour
environment by TGFbeta. Nat Rev Immunol. 10:554–567. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee JC, Lee KM, Kim DW and Heo DS:
Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies
impaired NK cytotoxicity in cancer patients. J Immunol.
172:7335–7340. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen CL, Tsukamoto H, Liu JC, Kashiwabara
C, Feldman D, Sher L, Dooley S, French SW, Mishra L, Petrovic L, et
al: Reciprocal regulation by TLR4 and TGF-β in tumor-initiating
stem-like cells. J Clin Invest. 123:2832–2849. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Oshimori N, Oristian D and Fuchs E: TGF-β
promotes heterogeneity and drug resistance in squamous cell
carcinoma. Cell. 160:963–976. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gorelik L and Flavell RA: Immune-mediated
eradication of tumors through the blockade of transforming growth
factor-beta signaling in T cells. Nat Med. 7:1118–1122. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu J, Lamouille S and Derynck R:
TGF-beta-induced epithelial to mesenchymal transition. Cell Res.
19:156–172. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shiota M, Zardan A, Takeuchi A, Kumano M,
Beraldi E, Naito S, Zoubeidi A and Gleave ME: Clusterin Mediates
TGF-β-induced epithelial-mesenchymal transition and metastasis via
twist1 in prostate cancer cells. Cancer Res. 72:5261–5272. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Labelle M, Begum S and Hynes RO: Direct
signaling between platelets and cancer cells induces an
epithelial-mesenchymal-like transition and promotes metastasis.
Cancer Cell. 20:576–590. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fang Y, Yu S and Braley-Mullen H: TGF-β
promotes proliferation of thyroid epithelial cells in IFN-γ(−/−)
mice by down-regulation of p21 and p27 via AKT pathway. Am J
Pathol. 180:650–660. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lu SL, Reh D, Li AG, Woods J, Corless CL,
Kulesz-Martin M and Wang XJ: Overexpression of transforming growth
factor beta1 in head and neck epithelia results in inflammation,
angiogenesis, and epithelial hyperproliferation. Cancer Res.
64:4405–4410. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tang B, Vu M, Booker T, Santner SJ, Miller
FR, Anver MR and Wakefield LM: TGF-beta switches from tumor
suppressor to prometastatic factor in a model of breast cancer
progression. J Clin Invest. 112:1116–1124. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lyons RM and Moses HL: Transforming growth
factors and the regulation of cell proliferation. Eur J Biochem.
187:467–473. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bravo SB, Pampin S, Cameselle-Teijeiro J,
Carneiro C, Domínguez F, Barreiro F and Alvarez CV: TGF-beta
induced apoptosis in human thyrocytes is mediated by p27kip1
reduction and is overridden in neoplastic thyrocytes by NF-kappaB
activation. Oncogene. 22:7819–7830. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chan S: Targeting the mammalian target of
rapamycin (mTOR): A new approach to treating cancer. Br J Cancer.
91:1420–1424. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yellen P, Saqcena M, Salloum D, Feng J,
Preda A, Xu L, Rodrik-Outmezguine V and Foster DA: High-dose
rapamycin induces apoptosis in human cancer cells by dissociating
mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Cell
Cycle. 10:3948–3956. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chatterjee A, Mukhopadhyay S, Tung K,
Patel D and Foster DA: Rapamycin-induced G1 cell cycle arrest
employs both TGF-β and Rb pathways. Cancer Lett. 360:134–140. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wan G, Mathur R, Hu X, Liu Y, Zhang X,
Peng G and Lu X: Long non-coding RNA ANRIL (CDKN2B-AS) is induced
by the ATM-E2F1 signaling pathway. Cell Signal. 25:1086–1095. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mazars P, Barboule N, Baldin V, Vidal S,
Ducommun B and Valette A: Effects of TGF-beta 1 (transforming
growth factor-beta 1) on the cell cycle regulation of human breast
adenocarcinoma (MCF-7) cells. FEBS Lett. 362:295–300. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Elbendary A, Berchuck A, Davis P,
Havrilesky L, Bast RC Jr, Iglehart JD and Marks JR: Transforming
growth factor beta 1 can induce CIP1/WAF1 expression independent of
the p53 pathway in ovarian cancer cells. Cell Growth Diff.
5:1301–1307. 1994.PubMed/NCBI
|
|
24
|
Seoane J, Le HV, Shen L, Anderson SA and
Massagué J.: Integration of Smad and forkhead pathways in the
control of neuroepithelial and glioblastoma cell proliferation.
Cell. 117:211–223. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gomis RR, Alarcón C, He W, Wang Q, Seoane
J, Lash A and Massagué J: A FoxO-Smad synexpression group in human
keratinocytes. Proc Natl Acad Sci USA. 103:pp. 12747–12752. 2006;
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen CR, Kang Y and Massagué J: Defective
repression of c-myc in breast cancer cells: A loss at the core of
the transforming growth factor beta growth arrest program. Proc
Natl Acad Sci USA. 98:pp. 992–999. 2001; View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y
and Wang XF: Transforming growth factor beta induces the
cyclin-dependent kinase inhibitor p21 through a p53-independent
mechanism. Proc Natl Acad Sci USA. 92:pp. 5545–5549. 1995;
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li JM, Nichols MA, Chandrasekharan S,
Xiong Y and Wang XF: Transforming growth factor beta activates the
promoter of cyclin-dependent kinase inhibitor p15INK4B through an
Sp1 consensus site. J Biol Chem. 270:26750–26753. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hosobuchi M and Stampfer MR: Effects of
transforming growth factor beta on growth of human mammary
epithelial cells in culture. In Vitro Cell Dev Biol. 25:705–713.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mo AD, Joseph H and Nolta JA: Molecular
mechanism of transforming growth factor beta-mediated cell-cycle
modulation in primary human CD34(+) progenitors. Blood. 99:499–506.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen Y, Zheng Y and Foster DA:
Phospholipase D confers rapamycin resistance in human breast cancer
cells. Oncogene. 22:3937–3942. 2003. View Article : Google Scholar : PubMed/NCBI
|
